Business Context and Reporting Period
This Form 8-K Current Report was filed by IMMUNIC, INC. (formerly Vital Therapies, Inc.) on April 29, 2019, reporting events that occurred on April 26, 2019. The registrant is a Delaware corporation with principal executive offices in Martinsried, Germany. The filing primarily addresses a change in senior management and the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and employment terms rather than financial performance metrics.
Material Changes
- Appointment of Interim CFO: On April 26, 2019, the Board elected Tamara A. Seymour as Interim Chief Financial Officer.
- Employment Terms: Ms. Seymour entered into a part-time, at-will employment agreement effective April 26, 2019.
- Compensation Structure: The agreement stipulates an hourly rate of $300 for approximately 100 hours of service per month.
- Benefits: Ms. Seymour is eligible for qualified retirement and medical plans (subject to plan terms). Until eligible for the company medical plan, the Company will reimburse 90% of her private medical insurance premium. She is not eligible for severance benefits or paid vacation.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond standard employment provisions. The agreement includes customary non-competition and non-solicitation clauses effective during employment and for six months thereafter. Confidentiality and invention assignment provisions also apply during and after the employment period.
Investor Verification Checklist
- Verify the exact start date and scope of duties for the new Interim CFO.
- Confirm the total monthly cash compensation obligation ($30,000 based on 100 hours at $300/hour).
- Review the press release (Exhibit 99.1) for additional context on the departure of the previous CFO or strategic reasons for the interim appointment.
- Monitor future filings for the transition from interim to permanent CFO status.